Model‐Informed Therapeutic Dose Optimization Strategies for Antibody–Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration–Approved Antibody–Drug Conjugates?

Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the cytotoxicity of a chemical agent. They represent a rapidly evolving area of oncology drug development and hold significant promise. There are currently nine ADCs on the market, more than half of which gained US Food and...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Michael Z., Lu, Dan, Kågedal, Matts, Miles, Dale, Samineni, Divya, Liu, Stephanie N., Li, Chunze
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596428/
https://www.ncbi.nlm.nih.gov/pubmed/33899934
http://dx.doi.org/10.1002/cpt.2278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596428/
https://www.ncbi.nlm.nih.gov/pubmed/33899934
http://dx.doi.org/10.1002/cpt.2278

Ejemplares similares